No Evidence Supports Contraindication of Colchicine in MTRR Homozygous Individuals
Colchicine can be safely used in individuals homozygous for MTRR gene variants affecting homocysteine metabolism, as there is no established contraindication based on this genetic polymorphism.
Evidence-Based Contraindications to Colchicine
The established contraindications and precautions for colchicine use are clearly defined in current guidelines and FDA labeling, and none include MTRR gene polymorphisms 1, 2, 3:
Absolute Contraindications
- Severe renal or hepatic impairment when used with P-glycoprotein or strong CYP3A4 inhibitors (cyclosporine, clarithromycin, ketoconazole, protease inhibitors except fosamprenavir) 1, 3
- Systemic fungal infections (for corticosteroids as alternative) 2
Relative Contraindications and Dose Adjustments
- Severe renal impairment: Colchicine and NSAIDs should be avoided 1
- Renal impairment with statin use: Increased risk of neurotoxicity and muscular toxicity; dose reduction required 1
- Hepatic impairment: Contraindicated when using P-gp or CYP3A4 inhibitors 2, 3
Understanding MTRR Polymorphisms and Homocysteine
The MTRR A66G polymorphism affects methionine synthase reductase, which maintains the activated cofactor for methionine synthase in homocysteine metabolism 4, 5. While research shows:
- The 66AA genotype moderately increases plasma homocysteine levels 4
- MTRR variants (66GG and 524TT) can cause hyperhomocysteinemia and folate deficiency 6
- These polymorphisms are associated with cardiovascular risk factors 4, 7, 8
However, there is no published evidence linking MTRR polymorphisms to altered colchicine metabolism, increased toxicity risk, or adverse outcomes with colchicine therapy.
Clinical Reasoning
The concern appears to stem from a misunderstanding about colchicine's mechanism and metabolism:
Colchicine metabolism: Colchicine is metabolized primarily by CYP3A4 and is a P-glycoprotein substrate 3. It has no direct interaction with folate metabolism pathways or MTRR enzyme function.
Homocysteine elevation: While MTRR polymorphisms may elevate homocysteine, this does not affect colchicine pharmacokinetics or safety profile.
Guideline silence: Neither EULAR 1, 9 nor American College of Physicians 2 guidelines mention genetic polymorphisms of folate metabolism as considerations for colchicine use.
Practical Management Approach
For patients with known MTRR homozygous variants requiring colchicine:
- Proceed with standard colchicine dosing based on indication (gout, FMF, cardiovascular disease)
- Monitor for standard colchicine toxicities: gastrointestinal symptoms, neuromuscular toxicity, blood dyscrasias 3
- Address hyperhomocysteinemia separately with folic acid, vitamin B12, and B6 supplementation as indicated 8, 6
- Avoid contraindicated drug combinations (P-gp/CYP3A4 inhibitors) regardless of MTRR status 1, 3
- Adjust dose for renal/hepatic impairment per standard protocols 1, 9
Common Pitfall to Avoid
Do not conflate genetic polymorphisms affecting homocysteine metabolism with colchicine safety. The two pathways are biochemically distinct. The real risks with colchicine relate to drug-drug interactions, organ dysfunction, and overdose—not folate cycle genetics 3, 10.